Drugs / CAF01
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02787109 | Jul 2016 → Jul 2017 | chlamydia trachomatis infectious disease | Statens Serum Institut | Completed | No outcome recorded |
| Phase 1 | NCT00922363 | Oct 2009 → Oct 2011 | tuberculosis | Statens Serum Institut | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CAF01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02787109 ↗ |
| Modality | Other / unclassified | “new Liposomal Adjuvant System, CAF01” NCT00922363 ↗ |
| Route | Intramuscular | “CTH522 chlamydia antigen adjuvanted with CAF01 for IM administration” NCT02787109 ↗ |